ADC Pharmaceutical Composition With Stable Linker Chemistry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) suffer from instability due to the thiosuccinimide linkage, leading to off-target toxicity and limited clinical applications, particularly in HER2-targeting therapies for cancer.
Innovation Solution
A new ADC formulation with a stable structure, incorporating a self-immolative spacer and specific linker chemistry, combined with a pharmaceutical composition including buffering agents and stabilizers, enhances stability and reduces toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If thiosuccinimide linkage is used to conjugate small-molecule drugs to targeting antibodies, then the ADC can be manufactured with established chemical methods, but the ADC stability deteriorates leading to off-target toxicity
Solution Approach 1:
The patent changes the chemical structure parameter of the linkage from thiosuccinimide to a stable peptide bond-based linkage. This structural parameter change transforms the unstable thiosuccinimide linkage into a stable peptide bond that resists retro-Michael addition and sulfhydryl-sulfhydryl exchange, thereby maintaining ADC stability while remaining manufacturable through peptide coupling methods
Solution Approach 2:
The patent creates a composite linkage structure combining multiple functional elements: a peptide bond for stability, a self-immolative spacer for controlled drug release, and specific amino acid sequences for enzymatic recognition. This composite structure integrates the advantages of chemical stability with controlled biological activation, resolving the contradiction between manufacturability and stability
2Ease of manufacture
If thiosuccinimide linkage is used in ADC formulation, then the ADC can be prepared through standard chemical conjugation, but the ADC generates harmful factors through retro-Michael addition and sulfhydryl-sulfhydryl exchange
Solution Approach 1:
The patent converts the potential harm of chemical instability into a benefit by designing a linkage that is intentionally stable against non-specific degradation but contains a controlled weakness - the self-immolative spacer that undergoes specific enzymatic-triggered decomposition. This transforms the problem of chemical reactivity into a solution where controlled decomposition enables targeted drug release without off-target toxicity
Solution Approach 2:
The patent introduces a self-immolative spacer as an intermediary component between the peptide bond and the cytotoxic drug. This intermediary acts as a controlled decomposition pathway that is stable under normal conditions but decomposes specifically under enzymatic conditions at the target site, preventing harmful retro-Michael addition while enabling controlled drug release
3Adaptability or versatility
If Enhertu is used for HER2-targeting therapy, then clinical benefit is achieved in patients with moderate/low HER2 expression, but interstitial lung disease occurs in no less than 10% of patients
Solution Approach 1:
The patent applies local quality by making the linkage stability context-dependent: highly stable in circulation to prevent off-target toxicity, but specifically decomposable at the target site through enzymatic recognition of the self-immolative spacer. This localized control of stability allows broader clinical applicability while reducing systemic harmful effects like interstitial lung disease
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new ADC formulation achieves high stability, long-term storage, and prevents toxicity, expanding its clinical applicability to a broader range of HER2-expressing cancers.
Implementation Method 1
L1 is a cleavable sequence 1 comprising an amino acid sequence capable of being cleaved by an enzyme
Implementation Method 2
the retro-Michael addition or the sulfhydryl-sulfhydryl exchange leads to the shedding of cytotoxins from ADCs
Implementation Method 3
the retro-Michael addition or the sulfhydryl-sulfhydryl exchange leads to the shedding of cytotoxins from ADCs
Data Source
AI summary
A pharmaceutical composition of an antibody drug conjugate, relating to the field of biopharmaceuticals.